Amino acid preferences of retroviral proteases for amino-terminal positions in a type 1 cleavage site

Journal of Virology

Volumn 82, Issue 20, 2008, Pages 10111-10117

  Eizert, Helga ^a   Bander, Pálma ^a   Bagossi, Péter ^a   Sperka, Tamás ^a   Miklóssy, Gabriella ^a   Boross, Péter ^a   Weber, Irene T ^b   Tözsér, József ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b GEORGIA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; AMINO ACID; GLUTAMINE; GLYCINE; ISOLEUCINE; LEUCINE; LYSINE; METHIONINE; PHENYLALANINE; PROTEINASE; SERINE; TYROSINE; VALINE; OLIGOPEPTIDE; PEPTIDE HYDROLASE; VIRUS PROTEIN;

AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ARTICLE; AVIAN MYELOBLASTOSIS VIRUS; BOVINE LEUKEMIA VIRUS; CONTROLLED STUDY; ENZYME DEGRADATION; ENZYME SPECIFICITY; EQUINE INFECTIOUS ANEMIA VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN T CELL LEUKEMIA VIRUS 1; MASON PFIZER MONKEY VIRUS; MOLECULAR MODEL; MOLONEY LEUKEMIA ONCOVIRUS; MOUSE MAMMARY TUMOR ONCOVIRUS; NONHUMAN; PHYLOGENETIC TREE; PRIORITY JOURNAL; RETROVIRUS; SARCOMA VIRUS; SIMIAN FOAMY VIRUS; AMINO ACID SUBSTITUTION; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; CLASSIFICATION; ENZYMOLOGY; GENETICS; HUMAN; METABOLISM; PHYLOGENY; PROTEIN CONFORMATION;

AVIAN MYELOBLASTOSIS VIRUS; BOVINE LEUKEMIA VIRUS; EQUINE INFECTIOUS ANEMIA VIRUS; HUMAN FOAMY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN T-LYMPHOTROPIC VIRUS 1; MASON-PFIZER MONKEY VIRUS; MOLONEY MURINE LEUKEMIA VIRUS; MOUSE MAMMARY TUMOR VIRUS; PRIMATES; RETROVIRIDAE; WALLEYE DERMAL SARCOMA VIRUS;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; AMINO ACIDS; ANIMALS; HIV-1; HUMANS; MOLECULAR STRUCTURE; OLIGOPEPTIDES; PEPTIDE HYDROLASES; PHYLOGENY; PROTEIN CONFORMATION; RETROVIRIDAE; SUBSTRATE SPECIFICITY; VIRAL PROTEINS;

EID: 53749106939     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.00418-08     Document Type: Article

References (41)

1. Bagossi, P., T. Sperka, A. Feher, J. Kádas, G. Zahuczky, G. Miklóssy, P. Boross, and J. Tözsér. 2005. Amino acid preferences for a critical substrate binding subsite of retroviral proteases in type 1 cleavage sites. J. Virol. 79:4213-4218.
2. Blaha, I., J. Tözsér, Y. Kim, T. D. Copeland, and S. Oroszlan. 1992. Solid phase synthesis of the proteinase of bovine leukemia virus. Comparison of its specificity to that of HIV-2 proteinase. FEBS Lett. 309:389-393.
3. Boross, P., J. Tozser, and P. Bagossi. 2006. Improved purification protocol for wild-type and mutant human foamy virus proteases. Protein Expr. Purif. 46:343-347.
4. Dunn, B. M., A. Gustchina, A. Wlodawer, and J. Kay. 1994. Subsite preferences of retroviral proteinases. Methods Enzymol. 241:254-278.
5. Feher, A., P. Boross, T. Sperka, G. Miklossy, J. Kadas, P. Bagossi, S. Oroszlan, I. T. Weber, and J. Tozser. 2006. Characterization of the murine leukemia virus protease and its comparison with the human immunodeficiency virus type 1 protease. J. Gen. Virol. 87:1321-1330.
6. Fehér, A., P. Boross, T. Sperka, S. Oroszlan, and J. Tözsér. 2004. Expression of the murine leukemia virus protease in fusion with maltose-binding protein in Escherichia coli. Protein Expr. Purif. 35:62-68.
7. Fenyöfalvi, G., P. Bagossi, T. D. Copeland, S. Oroszlan, P. Boross, and J. Tözsér. 1999. Expression and characterization of human foamy virus proteinase. FEBS Lett. 462:397-401.
8. Flügel, R. M., and K. I. Pfrepper. 2003. Proteolytic processing of foamy virus Gag and Pol proteins. Curr. Top. Microbiol. Immunol. 277:63-88.
9. Fodor, S. K., and V. M. Vogt. 2002. Characterization of the protease of a fish retrovirus, walleye dermal sarcoma virus. J. Virol. 76:4341-4349.
10. Gallo, R. C. 2002. Human retroviruses after 20 years: a perspective from the past and prospects for their future control. Immunol. Rev. 185:236-265.
11. Konvalinka, J., M. Löchelt, H. Zentgraf, R. M. Flügel, and H. G. Krausslich. 1995. Active foamy virus proteinase is essential for virus infectivity but not for formation of a Pol polyprotein. J. Virol. 69:7264-7268.
12. Linial, M. 2000. Why aren't foamy viruses pathogenic? Trends Microbiol. 8:284-289.
13. Louis, J. M., S. Oroszlan, and J. Tözsér. 1999. Stabilization from autoproteolysis and kinetic characterization of the human T-cell leukemia virus type 1 proteinase. J. Biol. Chem. 274:6660-6666.
14. Louis, J. M., I. T. Weber, J. Tözsér, G. M. Clore, and A. M. Gronenborn. 2000. HIV-1 protease: maturation, enzyme specificity, and drug resistance. Adv. Pharmacol. 49:111-146.
15. Macchi, B., E. Balestrieri, and A. Mastino. 2003. Effects of nucleoside-based antiretroviral chemotherapy on human T cell leukaemia/lymphotropic virus type 1 (HTLV-1) infection in vitro. J. Antimicrob. Chemother. 51:1327-1330.
16. Mellors, J. W. 1996. Closing in on human immunodeficiency virus-1. Nat. Med. 2:274-275.
17. Menendez-Arias, L., D. Gotte, and S. Oroszlan. 1993. Moloney murine leukemia virus protease: bacterial expression and characterization of the purified enzyme. Virology 196:557-563.
18. Menendez-Arias, L., I. T. Weber, J. Soss, R. W. Harrison, D. Gotte, and S. Oroszlan. 1994. Kinetic and modeling studies of subsites S4-S3′ of Moloney murine leukemia virus protease. J. Biol. Chem. 269:16795- 16801.
19. Menendez-Arias, L., M. Young, and S. Oroszlan. 1992. Purification and characterization of the mouse mammary tumor virus protease expressed in Escherichia coli. J. Biol. Chem. 267:24134-24139.
20. Mergia, A., and M. Heinkelein. 2003. Foamy virus vectors. Curr. Top. Microbiol. Immunol. 277:131-159.
21. Oroszlan, S., and R. B. Luftig. 1990. Retroviral proteinases. Curr. Top. Microbiol. Immunol. 157:153-185.
22. Prabu-Jeyabalan, M., E. Nalivaika, and C. A. Schiffer. 2002. Substrate shape determines specificity of recognition for HIV-1 protease: analysis of crystal structures of six substrate complexes. Structure 10:369-381.
23. Rethwilm, A. 2003. The replication strategy of foamy viruses. Curr. Top. Microbiol. Immunol. 277:1-26.
24. Ridky, T., and J. Leis. 1995. Development of drug resistance to HIV-1 protease inhibitors. J. Biol. Chem. 270:29621-29623.
25. Schechter, I., and A. Berger. 1967. On the size of the active site in proteases. I. Papain. Biochem. Biophys. Res. Commun. 27:157-162.
26. Sheremata, W. A., D. Benedict, D. C. Squilacote, A. Sazant, and E. DeFreitas. 1993. High-dose zidovudine induction in HTLV-I-associated myelopathy: safety and possible efficacy. Neurology 43:2125-2129.
27. Sperka, T., G. Miklossy, Y. Tie, P. Bagossi, G. Zahuczky, P. Boross, K. Matuz, R. W. Harrison, I. T. Weber, and J. Tozser. 2007. Bovine leukemia virus protease: comparison with human T-lymphotropic virus and human immunodeficiency virus proteases. J. Gen. Virol. 88:2052-2063.
28. Swanstrom, R., and J. Eron. 2000. Human immunodeficiency virus type-1 protease inhibitors: therapeutic successes and failures, suppression and resistance. Pharmacol. Ther. 86:145-170.
29. Tie, Y., P. I. Boross, Y. F. Wang, L. Gaddis, F. Liu, X. Chen, J. Tozser, R. W. Harrison, and I. T. Weber. 2005. Molecular basis for substrate recognition and drug resistance from 1.1 to 1.6 angstroms resolution crystal structures of HIV-1 protease mutants with substrate analogs. FEBS J. 272:5265-5277.
30. Tomasselli, A. G., and R. L. Heinrikson. 1994. Specificity of retroviral proteases: an analysis of viral and nonviral protein substrates. Methods Enzymol. 241:279-301.
31. Tözsér, J., P. Bagossi, I. T. Weber, T. D. Copeland, and S. Oroszlan. 1996. Comparative studies on the substrate specificity of avian myeloblastosis virus proteinase and lentiviral proteinases. J. Biol. Chem. 271:6781-6788.
32. Tözsér, J., A. Gustchina, I. T. Weber, I. Blaha, E. M. Wondrak, and S. Oroszlan. 1991. Studies on the role of the S4 substrate binding site of HIV proteinases. FEBS Lett. 279:356-360.
33. Tözsér, J., and S. Oroszlan. 2003. Proteolytic events of HIV-1 replication as targets for therapeutic intervention. Curr. Pharm. Des. 9:1803-1815.
34. Tözsér, J., I. T. Weber, A. Gustchina, I. Blaha, T. D. Copeland, J. M. Louis, and S. Oroszlan. 1992. Kinetic and modeling studies of S3-S3′ subsites of HIV proteinases. Biochemistry 31:4793-4800.
35. Tözsér, J., G. Zahuczky, P. Bagossi, J. M. Louis, T. D. Copeland, S. Oroszlan, R. W. Harrison, and I. T. Weber. 2000. Comparison of the substrate specificity of the human T-cell leukemia virus and human immunodeficiency virus proteinases. Eur. J. Biochem. 267:6287-6295.
36. UNAIDS. 2007. AIDS epidemic update: December 2007. http://data.unaids.org/pub/EPISlides/2007/2007_epiupdate_en.pdf.
37. Weber, I. T., J. Tözsér, J. Wu, D. Friedman, and S. Oroszlan. 1993. Molecular model of equine infectious anemia virus proteinase and kinetic measurements for peptide substrates with single amino acid substitutions. Biochemistry 32:3354-3362.
38. Wlodawer, A. 2002. Rational approach to AIDS drug design through structural biology. Annu. Rev. Med. 53:595-614.
39. Zabransky, A., M. Andreansky, O. Hruskova-Heidingsfeldova, V. Havlicek, E. Hunter, T. Ruml, and I. Pichova. 1998. Three active forms of aspartic proteinase from Mason-Pfizer monkey virus. Virology 245:250-256.
40. Zahuczky, G., P. Boross, P. Bagossi, G. Emri, T. D. Copeland, S. Oroszlan, J. M. Louis, and J. Tözsér. 2000. Cloning of the bovine leukemia virus proteinase in Escherichia coli and comparison of its specificity to that of human T-cell leukemia virus proteinase. Biochim. Biophys. Acta 1478:1-8.
41. Zamyatin, A. A. 1972. Protein volume in solution. Prog. Biophys. Mol. Biol. 24:107-123.